SCHEMBL3583643

SCHEMBL3583643

COC(=O)c1cc(Cl)ccc1NC(C)C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.53
NR4A2 P43354 2/20 0.47
SLC6A4 P31645 1/20 0.46
SLC6A3 Q01959 1/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
ALDH1A1 P00352 5/20 0.45
KDM4E B2RXH2 3/20 0.45
GLA P06280 1/20 0.45
GAA P10253 1/20 0.45
HSD17B10 Q99714 1/20 0.44
RXFP1 Q9HBX9 2/20 0.43
LMNA P02545 1/20 0.41
TGFBR1 P36897 1/20 0.41
KCNMA1 Q12791 1/20 0.40
HTT P42858 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C19 P33261 1/20 0.40
LPAR1 Q92633 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3580030 0.83 KDM4E (0.63) ALDH1A1KDM4EGLAGAAHSD17B10
SCHEMBL2609091 0.82 CA12 (0.59) KMT2AALDH1A1KDM4EGLAGAA
SCHEMBL4358899 0.81 KDM4E (0.67) ABL1NR4A2SLC6A4SLC6A3MEN1
SCHEMBL3708748 0.81 KDM4E (0.58) ABL1NR4A2SLC6A4SLC6A3MEN1
SCHEMBL12763922 0.81 KDM4E (0.43) KMT2AALDH1A1KDM4EGLAGAA
SCHEMBL29293876 0.79 HPGD (0.54) ABL1NR4A2SLC6A4SLC6A3MEN1
SCHEMBL5928677 0.79 KDM4E (0.71) ABL1NR4A2SLC6A4SLC6A3MEN1
SCHEMBL14605600 0.77 ABL1 (0.53) ABL1NR4A2SLC6A4SLC6A3MEN1
SCHEMBL27851463 0.77 ABL1 (0.53) ABL1NR4A2SLC6A4SLC6A3MEN1
SCHEMBL10800720 0.77 MAPT (0.64) ALDH1A1KDM4EGAALMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1984340-B1 ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2012-06-27 EP disclosed
US-7678818-B2 Anthranilamide and 2-amino-heteroarene-carboxamide compounds HOFFMANN-LA ROCHE INC. (US) 2010-03-16 US disclosed
EP-1984340-A1 ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-10-29 EP disclosed
US-20070219261-A1 Anthranilamide and 2-amino-heteroarene-carboxamide compounds HOFFMANN-LA ROCHE INC. 2007-09-20 US disclosed
WO-2007090752-A1 ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219261-A1 Anthranilamide and 2-amino-heteroarene-carboxamide compounds AADAT, AAAS, AADAC ABL1 198/4885NR4A2 2195/4885SLC6A4 3603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.